HC Wainwright raises BridgeBio price target to $120

0 min read | Published on 13 Jul 2026, 04:26 PM |Updated on 13 Jul 2026, 04:26 PM

Reviewed by

Radhika SScanX News Team

Key Highlights

HC Wainwright & Co. analyst Raghuram Selvaraju maintained a Buy rating on BridgeBio Pharma and raised the price target to $120 from $110, signaling a positive outlook.

*this image is generated using AI for illustrative purposes only.

HC Wainwright & Co. analyst Raghuram Selvaraju has maintained a Buy rating on BridgeBio Pharma (NASDAQ: BBIO) and increased the price target to $120 from $110. The revised target suggests an upside from the previous valuation set by the firm.

Analyst Rating and Price Target

The rating action reflects continued confidence in the company's prospects. The following table outlines the revised valuation:

Metric	Value
Rating	Buy
Previous Price Target	$110
New Price Target	$120

The adjustment in the price target indicates a revised outlook on the stock's performance potential.

What specific catalysts might drive BridgeBio Pharma's stock to reach the new $120 price target?

How could this rating upgrade influence investor sentiment and trading volume in the short term?

What are the potential risks that could prevent BridgeBio Pharma from achieving the revised valuation?

BridgeBio grants 83,283 RSUs to 37 new employees

1 min read | Published on 11 Jul 2026, 04:09 AM |Updated on 11 Jul 2026, 04:09 AM

Reviewed by

Ashish TScanX News Team

Add as a preferred
source on Google

Key Highlights

BridgeBio Pharma granted 83,283 RSUs to 37 new employees as an employment inducement under Nasdaq Rule 5635(c)(4). The grants, approved on July 7, 2026, vest quarterly starting August 16, 2027.

*this image is generated using AI for illustrative purposes only.

BridgeBio Pharma, Inc. granted 83,283 restricted stock units (RSUs) to 37 new employees as an employment inducement under Nasdaq Listing Rule 5635(c)(4). The compensation committee of BridgeBio’s board of directors approved the grants on July 7, 2026. The awards are intended as material inducements for the employees entering into employment with the company.

One-fourth of the shares underlying each employee’s RSUs will vest on August 16, 2027. The remaining shares will vest quarterly thereafter, subject to continued employment with BridgeBio or its subsidiaries on the vesting dates. The grants were made pursuant to the terms of the Plan, which was adopted by the board in November 2019 and amended and restated on February 10, 2023, and December 13, 2023.

Grant Details

Detail	Information
Total Shares Granted	83,283
Number of Employees	37
Grant Type	Restricted Stock Units (RSUs)
Initial Vesting Date	August 16, 2027
Subsequent Vesting	Quarterly
Regulatory Rule	Nasdaq Listing Rule 5635(c)(4)

Background

BridgeBio focuses on developing medicines for genetic conditions. The company utilizes a decentralized, hub-and-spoke model designed for speed and scalability. The equity awards are part of the company’s compensation strategy to attract new talent.

How will BridgeBio manage the potential dilution of existing shareholders as these RSUs vest over the coming years?

Does this hiring surge indicate that BridgeBio is preparing to advance specific drug candidates into late-stage clinical trials?

How will the company's burn rate be impacted by the addition of 37 new employees and their associated compensation costs?